argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?

This is a summary. Read the complete story at Yahoo Finance below.

Related Stories

marketsabout 5 hours ago

Micron could dethrone Nvidia and become the biggest driver of S&P 500 profit growth

Micron is increasingly important to the S&P 500, and its earnings report has become “a market event in and of itself.”

MarketWatch

marketsabout 6 hours ago

Look closer, and Wall Street’s rally is showing cracks

Major stock indexes hovering near records are masking a market straining under elevated oil prices, rising Treasury yields and a Federal Reserve bracing for additional interest-rate hikes.

MarketWatch

marketsabout 8 hours ago

Why the upcoming jobs report could send 10-year and 30-year Treasury yields surging

Another hot jobs report could also pressure the Federal Reserve to raise interest rates again in October.

MarketWatch